We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Medical Sciences/Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment
PeriodicalsMedical Sciences

Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment

Checking your access to this record.

Abstract & Overview

Abstract: Sensitizing mutations in epidermal growth factor receptor (EGFR) are associated with positive responses to anti-EGFR-targeted therapy, leading to a new era of treatment for non-small cell lung cancer (NSCLC). Exon 19 deletions and exon 21 L858R substitutions are the most common mutations, accounting for approximately 90% mutations in NSCLC; these are termed classic mutations and result in high sensitivity to tyrosine kinase inhibitors (TKIs). Other EGFR mutations are termed uncommon EGFR mutations, of which G719X, S768I, L861Q, exon 20 insertions, and complex mutations are the most frequent. G719X, S768I, and L861Q are point mutations and those that exist with complex mutations are sensitive to first-generation TKIs. A prospective analysis demonstrated that afatinib, a second-generation TKI, led to a better prognosis in some patients with NSCLC compared to first-generation TKIs. Chemotherapy used to be the traditional choice for patients carrying exon 20 insertions; however, with the development of novel targeted drugs, the role of chemotherapy is changing. Tremendous progress has also been made in clinical trials on immunotherapy treatment of uncommon EGFR mutations. The treatment for patients with NSCLC harboring uncommon EGFR mutations remains a subject of debate and the sensitivity of uncommon EGFR mutations to TKIs is still unclear. Here, we summarized recent data in the literature and provide an overview of the clinical characteristics, incidence, and outcomes of patients harboring G719X, S768I, L861Q, exon 20 insertions, and complex mutations who were treated with TKIs, chemotherapy, or immunotherapy.

Cite this record

Tianli Zhang, Bing Wan, Yuan Zhao, Chuling Li, Hongbing Liu, Tangfeng Lv, et al. (2019). Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Translational Lung Cancer Research, 8(3), 302–316. https://doi.org/10.21037/tlcr.2019.04.12

Copy in another style

Zhang, T., Wan, B., Zhao, Y., Li, C., Liu, H., Lv, T., Zhan, P., & Song, Y. (2019). Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Translational Lung Cancer Research, 8(3), 302–316. https://doi.org/10.21037/tlcr.2019.04.12
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.